Nanocarrier-based activation of necroptotic cell death potentiates cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Nanotechnology

Background:

• Immunological checkpoint inhibitors (ICIs) show potent anti-tumor effects but face challenges due to low tumor immunogenicity, leading to resistance.
• Immunogenic cell death (ICD) can enhance T cell responses, suggesting combination therapy with ICIs may improve efficacy.

Purpose of the Study:

• To develop a synergistic strategy combining necroptotic cell death activation with immune checkpoint inhibitors for enhanced anti-tumor immunity.
• To utilize liposomes as nanoplatforms for targeted delivery of Tumor Necrosis Factor-alpha (TNF-α).

Main Methods:

• Liposomes were loaded with TNF-α for in vivo tumor targeting and retention.
• Tumor cells were treated with TNF-α-loaded liposomes to induce ICD, characterized by HMGB1 and LDH release.
• The combination therapy involved TNF-α-induced cell death followed by checkpoint blockade therapy.

Main Results:

• TNF-α-loaded liposomes successfully induced ICD hallmarks in tumor cells.
• Tumor cell necrosis led to the release of tumor-specific antigens, enhancing dendritic cell activation.
• The combination therapy significantly increased T cell infiltration and achieved substantial tumor reduction.

Conclusions:

• TNF-α-loaded liposomes effectively activate ICD and act as an endogenous vaccine.
• This synergistic strategy enhances anti-tumor immunity and improves the efficacy of anti-PD-1/PD-L1 therapy.
• The approach offers a promising method to overcome resistance to mono-immunotherapy in cancer treatment.